[1]Burke,PatrickJ.;Koch,TadH.[JournalofMedicinalChemistry,2004,vol.47,#5,p.1193-1206]
[2]Burke,PatrickJ.;Kalet,BrianT.;Koch,TadH.[JournalofMedicinalChemistry,2004,vol.47,#26,p.6509-6518]
[3]CurrentPatentAssignee:ACCUTARBIOTECHNOLOGYINC;ACCUTARBIOTECHNOLOGYINC-US2020/157078,2020,A1Locationinpatent:Paragraph0575;0578
[1]Burke,PatrickJ.;Koch,TadH.[JournalofMedicinalChemistry,2004,vol.47,#5,p.1193-1206]
[1]Burke,PatrickJ.;Koch,TadH.[JournalofMedicinalChemistry,2004,vol.47,#5,p.1193-1206]
[1]Burke,PatrickJ.;Koch,TadH.[JournalofMedicinalChemistry,2004,vol.47,#5,p.1193-1206]
[1]Burke,PatrickJ.;Kalet,BrianT.;Koch,TadH.[JournalofMedicinalChemistry,2004,vol.47,#26,p.6509-6518]
Title: Goetz MP, et al. Tamoxifen, endoxifen, and CYP2D6: the rules for evaluating a predictive factor. Oncology (Williston Park). 2009 Dec;23(14):1233-4, 1236.
Title: Wu X, et al. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Cancer Res. 2009 Mar 1;69(5):1722-7.